PARP1 and neoplasm: Kim and colleagues tested a new in-vivo delivery vehicle for the disruption of Poly (ADP-ribose) polymerase-1 (PARP-1) expression by using tumor-derived EVs loaded with Cas9 and PARP-1 sgRNA-encoding plasmids.